Comparison of the structure and function of phospholamban and the arginine-14 deficient mutant associated with dilated cardiomyopathy

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Hughes, Eleri ^a   Middleton, David A ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYCLIC AMP DEPENDENT PROTEIN KINASE; MUTANT PROTEIN; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SERINE 16; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; LIPID BILAYER;

ARTICLE; CALCIUM HOMEOSTASIS; CATALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOPLASM; HEART MUSCLE CONTRACTILITY; HETEROZYGOTE; HUMAN; INTERMETHOD COMPARISON; LIPID MEMBRANE; PHOSPHOLIPID BILAYER; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SARCOPLASMIC RETICULUM; WILD TYPE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVATION; GENETICS; LIPID BILAYER; METABOLISM; MUTATION; NUCLEAR MAGNETIC RESONANCE; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS;

CALCIUM-BINDING PROTEINS; CARDIOMYOPATHY, DILATED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; HUMANS; LIPID BILAYERS; MODELS, MOLECULAR; MUTATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHOSPHORYLATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 84907164418     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106746     Document Type: Article

References (49)

1. Wegener AD, Jones LR (1984) Phosphorylation-induced mobility shift in phospholamban in sodium dodecyl sulfate-polyacrylamide gels - Evidence for a protein-structure consisting of multiple identical phosphorylatable subunits. J Biol Chem 259: 1834-1841.
2. Fujii J, Ueno A, Kitano K, Tanaka S, Kadoma M, et al. (1987) Complete complementary DNA-derived amino acid sequence of canine cardiac phospholamban. J Clin Invest 79: 301-304.
3. Tada M, Inui M (1983) Regulation of calcium transport by the ATPase-phospholamban system. J Mol Cell Cardiol 15: 565-575.
4. Koss KL, Kranias EG (1996) Phospholamban: A prominent regulator of myocardial contractility. Circ Res 79: 1059-1063.
5. James P, Inui M, Tada M, Chiesi M, Carafoli E (1989) Nature and site of phospholamban regulation of the Ca-2+ pump of sarcoplasmic-reticulum. Nature 342: 90-92.
6. Jackson WA, Colyer J (1996) Translation of Ser(16) and Thr(17) phosphorylation of phospholamban into Ca2+-pump stimulation. Biochem J 316: 201-207.
7. Negash S, Yao Q, Sun HY, Li JH, Bigelow DJ, et al. (2000) Phospholamban remains associated with the Ca2+- and Mg2+- dependent ATPase following phosphorylation by cAMP-dependent protein kinase. Biochem J 351: 195-205.
8. Kimura Y, Kurzydlowski K, Tada M, MacLennan DH (1997) Phospholamban inhibitory function is activated by depolymerization. J Biol Chem 272: 15061-15064.
9. Robia SL, Campbell KS, Kelly EM, Hou ZJ, Winters DL, et al. (2007) Forster transfer recovery reveals that phospholamban exchanges slowly from pentamers but rapidly from the SERCA regulatory complex. Circulation Research 101: 1123-1129.
10. Verardi R, Shi L, Traaseth NJ, Walsh N, Veglia G (2011) Structural topology of phospholamban pentamer in lipid bilayers by a hybrid solution and solid-state NMR method. Proceedings of the National Academy of Sciences of the United States of America 108: 9101-9106.
11. Zamoon J, Mascioni A, Thomas DD, Veglia G (2003) NMR solution structure and topological orientation of monomeric phospholamban in dodecylphosphocholine micelles. Biophys J 85: 2589-2598.
12. Traaseth NJ, Shi L, Verardi R, Mullen DG, Barany G, et al. (2009) Structure and topology of monomeric phospholamban in lipid membranes determined by a hybrid solution and solid-state NMR approach. Proceedings of the National Academy of Sciences of the United States of America 106: 10165-10170.
13. Abu-Baker S, Lu JX, Chu S, Shetty KK, Gor'kov PL, et al. (2007) The structural topology of wild-type phospholamban in oriented lipid bilayers using N-15 solid-state NMR spectroscopy. Protein Science 16: 2345-2349.
14. Gustavsson M, Traaseth NJ, Karim CB, Lockamy EL, Thomas DD, et al. (2011) Lipid-Mediated Folding/Unfolding of Phospholamban as a Regulatory Mechanism for the Sarcoplasmic Reticulum Ca(2+)-ATPase. Journal of Molecular Biology 408: 755-765.
15. Masterson LR, Yu T, Shi L, Wang Y, Gustavsson M, et al. (2011) cAMP-Dependent Protein Kinase A Selects the Excited State of the Membrane Substrate Phospholamban. Journal of Molecular Biology 412: 155-164.
16. Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, et al. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299: 1410-1413.
17. Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, et al. (2006) A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America 103: 1388-1393.
18. van der Zwaag PA, van Rijsingen IAW, Asimaki A, Jongbloed JDH, van Veldhuisen DJ, et al. (2012) Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. European Journal of Heart Failure 14: 1199-1207.
19. Ha KN, Masterson LR, Hou ZJ, Verardi R, Walsh N, et al. (2011) Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A. Proceedings of the National Academy of Sciences of the United States of America 108: 2735-2740.
20. Schmitt JP, Ahmad F, Lorenz K, Hein L, Schulz S, et al. (2009) Alterations of Phospholamban Function Can Exhibit Cardiotoxic Effects Independent of Excessive Sarcoplasmic Reticulum Ca2+-ATPase Inhibition. Circulation 119: 436-U132.
21. Sharma P, Ignatchenko V, Grace K, Ursprung C, Kislinger T, et al. (2010) Endoplasmic Reticulum Protein Targeting of Phospholamban: A Common Role for an N-Terminal Di-Arginine Motif in ER Retention? Plos One 5.
22. Haghighi K, Pritchard T, Bossuyt J, Waggoner JR, Yuan QY, et al. (2012) The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase. Journal of Molecular and Cellular Cardiology 52: 773-782.
23. Ceholski DK, Trieber CA, Holmes CFB, Young HS (2012) Lethal, Hereditary Mutants of Phospholamban Elude Phosphorylation by Protein Kinase A. Journal of Biological Chemistry 287: 26596-26605.
24. East J, Lee A (1982) Lipid selectivity of the Ca2+ and Mg2+ ion dependent adenosinetriphosphate studied with fluorescence quenching by a bromine phospholipid. Biochemistry 21: 4144-4151.
25. Chiu J, March PE, Lee R, Tillett D (2004) Site-directed, Ligase-Independent Mutagenesis (SLIM): a single-tube methodology approaching 100% efficiency in 4 h. Nucleic Acids Research 32.
26. Buck B, Zamoon J, Kirby TL, DeSilva TM, Karim C, et al. (2003) Overexpression, purification, and characterization of recombinant Ca-ATPase regulators for high-resolution solution and solid-state NMR studies. Protein Expression and Purification 30: 253-261.
27. Douglas JL, Trieber CA, Afara M, Young HS (2005) Rapid, high-yield expression and purification of Ca2+-ATPase regulatory proteins for high-resolution structural studies. Protein Expr Purif 40: 118-125.
28. Hughes E, Edwards R, Middleton DA (2010) Heparin-derived oligosaccharides interact with the phospholamban cytoplasmic domain and stimulate SERCA function. Biochemical and Biophysical Research Communications 401: 370-375.
29. Hu J, Qin H, Li C, Sharma M, Cross TA, et al. (2007) Structural biology of transmembrane domains: Efficient production and characterization of transmembrane peptides by NMR. Protein Science 16: 2153-2165.
30. Dalton KA, Pilot JD, Mall S, East JM, Lee AG (1999) Anionic phospholipids decrease the rate of slippage on the Ca2+-ATPase of sarcoplasmic reticulum. Biochem J 342: 431-438.
31. Levy D, Gulik A, Bluzat A, Rigaud JL (1992) Reconstitution of the sarcoplasmic-reticulum Ca2+-Atpase - mechanisms of membrane-protein insertion into liposomes during reconstitution procedures involving the use of detergents. Biochim Biophys Acta 1107: 283-298.
32. Hughes E, Middleton DA (2003) Solid-state NMR reveals structural changes in phospholamban accompanying the functional regulation of Ca2+-ATPase. J Biol Chem 278: 20835-20842.
33. Toyofuku T, Kurzydlowski K, Tada M, Maclennan DH (1994) Amino-acids Glu(2) to Ile(18) in the cytoplasmic domain of phospholamban are essential for functional association with the Ca2+-Atpase of sarcoplasmic-reticulum. J Biol Chem 269: 3088-3094.
34. Yoda A, Hokin L (1970) On reversibility of binding cardiotonic steroids to a partially purified (Na+K)-activated adenosinetriphosphate from beef brain. Biochemical and Biophysical Research Communications 40: 880-886.
35. Reddy LG, Cornea RL, Winters DL, McKenna E, Thomas DD (2003) Defining the molecular components of calcium transport regulation in a reconstituted membrane system. Biochemistry 42: 4585-4592.
36. Li M, Cornea RL, Autry JM, Jones LR, Thomas DD (1998) Phosphorylation-induced structural change in phospholamban and its mutants, detected by intrinsic fluorescence. Biochemistry 37: 7869-7877.
37. Cook P, Maynard E, Kent E, Hartl T, Roskoski R (1982) Adenosine cyclic 3', 5' - monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. Biochemistry 21: 5794-5799.
38. Ceholski DK, Trieber CA, Young HS (2012) Hydrophobic Imbalance in the Cytoplasmic Domain of Phospholamban Is a Determinant for Lethal Dilated Cardiomyopathy. Journal of Biological Chemistry 287: 16521-16529.
39. Andronesi OC, Becker S, Seidel K, Heise H, Young HS, et al. (2005) Determination of membrane protein structure and dynamics by magic-angle-spinning solid-state NMR spectroscopy. Journal of the American Chemical Society 127: 12965-12974.
40. Hughes E, Clayton JC, Middleton DA (2009) Cytoplasmic residues of phospholamban interact with membrane surfaces in the presence of SERCA: A new role for phospholipids in the regulation of cardiac calcium cycling? Biochimica Et Biophysica Acta-Biomembranes 1788: 559-566.
41. Hughes G, Starling AP, Sharma RP, East JM, Lee AG (1996) An investigation of the mechanism of inhibition of the Ca2+- ATPase by phospholamban. Biochem J 318: 973-979.
42. Waggoner JR, Huffman J, Froehlich JP, Mahaney JE (2007) Phospholamban inhibits Ca-ATPase conformational changes involving the E2 intermediate. Biochemistry 46: 1999-2009.
43. Cantilina T, Sagara Y, Inesi G, Jones L (1993) Comparative studies of cardiac and skeletal sarcoplasmic reticulum ATPases. Effect of a phospholamban antibody on enzyme activation by Ca2+. J Biol Chem 268: 17018-17025.
44. Akin BL, Chen ZH, Jones LR (2010) Superinhibitory Phospholamban Mutants Compete with Ca2+ for Binding to SERCA2a by Stabilizing a Unique Nucleotide-dependent Conformational State. Journal of Biological Chemistry 285: 28540-28552.
45. Lockamy EL, Cornea RL, Karim CB, Thomas DD (2011) Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure. Biochemical and Biophysical Research Communications 408: 388-392.
46. Gruber SJ, Haydon S, Thomas DD (2012) Phospholamban mutants compete with wild type for SERCA binding in living cells. Biochemical and Biophysical Research Communications 420: 236-240.
47. Mahaney JE, Autry JM, Jones LR (2000) Kinetics studies of the cardiac Ca- ATPase expressed in Sf21 cells: New insights on Ca-ATPase regulation by phospholamban. Biophys J 78: 1306-1323.
48. Zvaritch E, Backx PH, Jirik F, Kimura Y, de Leon S, et al. (2000) The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility. J Biol Chem 275: 14985-14991.
49. Sayadi M, Tanizaki S, Feig M (2010) Effect of Membrane Thickness on Conformational Sampling of Phospholamban from Computer Simulations. Biophysical Journal 98: 805-814.